Tadalafil Tablet
Product Images NDC 72789-396

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-396). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789396 Label (72789396)

Packaging label for Tadalafil USP 20 mg tablets by PD-Rx Pharmaceuticals, Inc. The label specifies a package containing 15 oral tablets. Key details include the NDC 72789-396-15, lot number D24F93, and expiration date 07/2027. The label also includes warnings about keeping the medication out of reach of children and directs patients to see the package insert for dosage and storage information.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline scores, with Tadalafil demonstrating a greater decrease than placebo, reaching statistical significance (p<0.01) at 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing blood pressure changes over time for standing and supine positions. The graphs illustrate differences in systolic and diastolic blood pressure (in mmHg) between tadalafil and placebo groups over 96 hours, with time in hours on the x-axes and pressure difference on the y-axes.*

FDA Label Image

Figure2 (Tadalafil Figure2)

A pharmacodynamic chart depicting standing and supine systolic blood pressure changes over 24 hours post-dose. The graph compares Tadalafil 20 mg plus doxazosin 8 mg and placebo plus doxazosin 8 mg, showing blood pressure variation in mmHg on the y-axis and time post-dose in hours on the x-axis.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting changes in systolic blood pressure (mmHg) over 12 hours following administration of tadalafil or placebo, combined with doxazosin. The graph compares systolic BP variations across different doses of tadalafil (8 mg and 20 mg) and placebo, all administered at 08:00, showing trends and fluctuations in blood pressure over time.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg doses following 5 consecutive days of administration. Concentration peaks early and declines over time with variations among dosing regimens.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph depicting the change from baseline in IPSS Total Score over a 12-week treatment duration. It compares Tadalafil 5 mg with placebo, showing Tadalafil resulting in a greater reduction in score. The vertical axis represents the change in score, and the horizontal axis denotes weeks of treatment. Statistical significance (p<0.01) is indicated.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis represents change in score. Tadalafil shows a greater decrease over time compared to placebo, with a significance marker at p<0.01.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph showing the least-squares mean change from baseline over 26 weeks of therapy compared between Tadalafil/Finasteride and Placebo/Finasteride groups. The graph plots weeks on the x-axis and LS mean change on the y-axis, illustrating comparative trends over time with statistical significance indicators for the differences.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil, showing its molecular framework including fused rings and characteristic functional groups as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.